Search clinical trials for: binimetinib

Total 106 results

Spanish Cooperative Group for the Treatment of...
Merck, S.L., Spain; Pierre Fabre Ibérica, S.A.

Not yet recruiting

Study to Evaluate the Efficacy and Safety of Cetuximab in Combination With Encorafenib Plus Binimetinib as Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer (CEBBRA)

Colorectal Cancer
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd

Recruiting

Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) (Perfume)

Pancreatic Cancer | Low-grade Glioma

Japan
Pfizer
Merck Sharpe & Dohme LLC

Recruiting

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

Melanoma

Italy, Spain, Czechia, Germany, Slovakia, Poland, United Kingdom
Leiden University Medical Center
Pierre Fabre Laboratories

Recruiting

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Melanoma Stage III | In-Transit Metastasis of Cutaneous Melanoma

Netherlands
UNICANCER
Cancer Research UK; National Cancer Institute, France; Servier; Pierre Fabre Medicament and other collaborators

Not yet recruiting

Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10)

Biliary Tract Neoplasms

United Kingdom, France, Belgium
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Gallbladder Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Malignant Solid Neoplasm | Stage IV Pancreatic Cancer AJCC v8 | Pancreatic Carcinoma | Stage IV Ovarian Cancer AJCC v8 | Ovarian Low Grade Serous Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
AIO-Studien-gGmbH
Universitätsklinikum Hamburg-Eppendorf; Merck Serono GmbH, Germany; Pierre Fabre...

Recruiting

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF)

Colorectal Cancer | Colon Cancer | BRAF V600 Mutation | BRAF V600E | Localized Cancer

Germany
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Glioma | Melanoma | Thyroid Cancer | Non-Small-Cell Lung Cancer

United States, Canada, Israel
Dr. Ronnie Shapira

Not yet recruiting

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma (MK3475-C01)

Metastatic Melanoma | Malignant Melanoma | Immunotherapy | Malignant Melanoma Stage IV | BRAF V600E
Nationwide Children's Hospital
Children's Hospital Colorado

Recruiting

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Adamantinous Craniopharyngioma | Recurrent Adamantinomatous Craniopharyngioma

United States, United Kingdom, Australia, Canada, Germany, Netherlands
Pfizer

Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Solid Tumors

United States, Spain, Canada, Italy, Australia, Hungary, Netherlands, United Kingdom, Germany, Brazil, Korea, Republic of, Portugal, France, Japan, Israel, Slovakia, Czechia
H. Lee Moffitt Cancer Center and Research Institute
Pfizer; Acrotech Biopharma Inc.

Recruiting

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Triple-Negative Breast Carcinoma

United States
CCTU- Cancer Theme
Pierre Fabre Medicament

Not yet recruiting

Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (PREMIUM)

Melanoma | Cancer

United Kingdom
M.D. Anderson Cancer Center

Recruiting

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Kinnate Biopharma

Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Melanoma | Non-small Cell Lung Cancer | Solid Tumor, Adult

United States, Australia, France, Spain, Taiwan, Korea, Republic of, China, Netherlands
Deciphera Pharmaceuticals LLC

Recruiting

A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors

Melanoma | Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Pancreatic Ductal Adenocarcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Recruiting

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Melanoma Stage IV | BRAF V600 Mutation | Melanoma Stage III

United States
Peter MacCallum Cancer Centre, Australia

Recruiting

Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (CELEBRATE)

Melanoma | Metastasis

Australia
Jacobio Pharmaceuticals Co., Ltd.
AbbVie

Recruiting

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

NSCLC | Solid Tumor

United States
University of California, San Francisco
Array BioPharma

Recruiting

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Melanoma Stage IV | Melanoma Stage III

United States
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)

Non Small Cell Lung Cancer | BRAF V600E

France
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Metastatic Melanoma | Metastatic Cutaneous Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; Array BioPharma

Recruiting

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Hairy Cell Leukemia

United States
Massachusetts General Hospital
Pfizer; Array BioPharma

Recruiting

Lorlatinib Combinations in Lung Cancer

NSCLC | Lung Cancer | Relapsed Cancer | Resistant Cancer | MET Amplification | Anaplastic Lymphoma Kinase Gene Translocation | ROS1 Rearrangement

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
UNICANCER
Merck Sharp & Dohme LLC; Pierre Fabre Medicament; European Association of Dermato...

Recruiting

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB)

Brain Metastases | Malignant Melanoma | BRAF V600 Mutation

France
Providence Health & Services

Recruiting

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

BRAF V600E Mutation Present | Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Refractory Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | BRAF NP_004324.2:p.V600M | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Carcinoma...

United States
Pierre Fabre Pharma GmbH
Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment (BERING)

Melanoma Stage IV | Melanoma Stage III

Austria, Germany, Switzerland
University Health Network, Toronto

Recruiting

Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Non-small Cell Carcinoma

Canada
Hope Rugo, MD
Johns Hopkins University; Pfizer; Gilead Sciences; Hoosier Cancer Research Network and other collaborators

Recruiting

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Unresectable Breast Carcinoma | Stage IIIC Breast Cancer | Triple-Negative Breast Carcinoma | Stage III Breast Cancer

United States
IDEAYA Biosciences

Recruiting

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Colorectal Cancer | Metastatic Uveal Melanoma | Cutaneous Melanoma | Other Solid Tumors

United States, Australia, Canada
Massachusetts General Hospital
Stand Up To Cancer

Recruiting

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Metastatic Colon Cancer | Stage III Colon Cancer

United States
Inge Marie Svane

Recruiting

Melanoma Metastasized to the Brain and Steroids (MEMBRAINS)

Malignant Melanoma

Denmark
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Skin Cancer | Melanoma (Skin) | Skin Carcinoma | Skin Melanoma

United States
Strata Oncology
Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences

Active, not recruiting

Strata PATH™ (Precision Indications for Approved Therapies) (Strata PATH)

Cancer | Advanced Solid Tumor

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
Pfizer
Merck Sharp & Dohme LLC

Active, not recruiting

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Melanoma

France, United States, Hungary, Italy, Spain, Czechia, Belgium, Germany, New Zealand, Canada, Austria, Israel, Poland, Russian Federation, Turkey, Switzerland, South Africa, Slovakia, United Kingdom, Ukraine, Brazil, Argentina, Bulg... and more
Pfizer

Completed

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US (OCEANMIST)

Melanoma

United States
Pfizer

Completed

A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings

Metastatic Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
University Health Network, Toronto

Active, not recruiting

Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER)

Solid Tumor

Canada
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Metastatic Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent Pancreatic Carcinoma | Locally Advanced Pancreatic Carcinoma

United States
Pfizer

Active, not recruiting

PF-07284892 in Participants With Advanced Solid Tumors

Solid Tumor

United States
Pfizer

Active, not recruiting

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Spain, Netherlands, Korea, Republic of, Italy

Search clinical trials for: binimetinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations